Rheumatology International

, Volume 32, Issue 11, pp 3675–3678 | Cite as

Repeat etanercept administration restores clinical response of patients with rheumatoid arthritis

  • Hiroki Wakabayashi
  • Akihiro Sudo
  • Yosuke Nishioka
  • Masahiro Hasegawa
  • Yukari Minami
  • Kusuki Nishioka
Short Communication

Abstract

We determined whether repeated treatment with the tumor necrosis factor-α (TNF-α) antagonist etanercept can be effective after an initial clinical response to this drug is lost. We describe three female patients with active, refractory rheumatoid arthritis who were administered with a second course of etanercept after eventually becoming refractory to a first course. Disease activity was high in all three patients before initial etanercept therapy, and each of them had clinically responded by 24 weeks. However, the initial clinical effect was lost between 1.5 and 3.5 years thereafter, and tocilizumab was administered, but the effect was lost again between 3 and 18 months later. Two patients did not respond to subsequent treatment with adalimumab and infliximab. Etanercept administered once again reduced disease activity in all three patients, none of whom developed any acute side effects. Etanercept re-administration significantly improved clinical disease activity and inflammatory parameters in three patients with RA who were refractory to biological anti-TNF agents.

Keywords

Rheumatoid arthritis Biological agent Refractory disease Etanercept Re-administration 

References

  1. 1.
    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343:1594–1602PubMedCrossRefGoogle Scholar
  2. 2.
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586–1593PubMedCrossRefGoogle Scholar
  3. 3.
    Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, Nawata M, Kameda H, Iwata S, Amano K, Yamanaka H (2008) Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol 18:146–152PubMedCrossRefGoogle Scholar
  4. 4.
    Lee YH, Woo JH, Rho YH, Choi SJ, Ji JD, Song GG (2008) Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int 28:553–559PubMedCrossRefGoogle Scholar
  5. 5.
    Wakabayashi H, Sudo A, Hasegawa M, Oka H, Uchida A, Nishioka K (2010) Retrospective clinical study of the efficacy of lower-dose methotrexate and infliximab therapy in patients with rheumatoid arthritis. Clin Rheumatol 29:671–675PubMedCrossRefGoogle Scholar
  6. 6.
    Wiens A, Correr CJ, Venson R, Otuki MF, Pontarolo R (2010) A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. Rheumatol Int 30:1063–1070PubMedCrossRefGoogle Scholar
  7. 7.
    Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW (2007) Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 66(3):iii56–iii60Google Scholar
  8. 8.
    Haraoui B, Keystone EC, Thorne JC, Pope JE, Chen I, Asare CG, Leff JA (2004) Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 31:2356–2359PubMedGoogle Scholar
  9. 9.
    Laas K, Peltomaa R, Kautiainen H, Leirisalo-Repo M (2008) Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol 27:927–932PubMedCrossRefGoogle Scholar
  10. 10.
    Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Yoshinaga T, Freundlich B, Suzukawa M (2011) Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study. Rheumatol Int. doi:10.1007/s00296-011-1807-0
  11. 11.
    Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfá E (2010) Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 38:82–89PubMedCrossRefGoogle Scholar
  12. 12.
    Barrera MV, Habicheyn S, Mendiola MV, Herrera Ceballos E (2008) Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol 18:683–687PubMedGoogle Scholar
  13. 13.
    Ortonne JP, Taïeb A, Ormerod AD, Robertson D, Foehl J, Pedersen R, Molta C, Freundlich B (2009) Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol 161:1190–1195PubMedCrossRefGoogle Scholar
  14. 14.
    Daudén E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, Pedersen R, Estojak J, Boggs R (2009) Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 23:1374–1382PubMedCrossRefGoogle Scholar
  15. 15.
    Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–975PubMedCrossRefGoogle Scholar
  16. 16.
    Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics Register (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56:13–20PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Hiroki Wakabayashi
    • 1
  • Akihiro Sudo
    • 1
  • Yosuke Nishioka
    • 2
  • Masahiro Hasegawa
    • 1
  • Yukari Minami
    • 2
  • Kusuki Nishioka
    • 3
  1. 1.Department of Orthopaedic SurgeryMie University Graduate School of MedicineTsuJapan
  2. 2.Clinical Research Institute for Rheumatic DiseaseShimaJapan
  3. 3.Institute of Medical Science, Tokyo Medical UniversityTokyoJapan

Personalised recommendations